Literature DB >> 2220860

Stability of ranitidine in intravenous admixtures stored frozen, refrigerated, and at room temperature.

J T Stewart1, F W Warren, S M Johnson, L J Galante.   

Abstract

The stability of ranitidine in concentrations of 0.5, 1.0, and 2.0 mg/mL in admixtures with commonly used i.v. fluids was studied. The admixture vehicles were 0.9% sodium chloride, 5% dextrose, 10% dextrose, 5% dextrose and 0.45% sodium chloride, and 5% dextrose with lactated Ringer's (DLR) injections in polyvinyl chloride bags. Three bags were prepared for each test solution and stored under each of the following conditions: seven days at room temperature (23 +/- 1 degrees C) in normal laboratory lighting, 30 days at 4 degrees C, and 60 days at -20 degrees C followed by either seven days at room temperature (in light) or 14 days at 4 degrees C. Ranitidine content was determined by high-performance liquid chromatography at several intervals. Color, clarity, and pH were also examined. Ranitidine concentrations remained greater than or equal to 90% of initial concentrations under all storage conditions except in the frozen DLR admixtures. Drug loss in the DLR admixtures was greatest at the lower ranitidine concentrations. The only visual changes were yellow color in the thawed DLR admixtures and those containing ranitidine 2.0 mg/mL in 5% dextrose and 0.45% sodium chloride. Slight increases in the pH of some admixtures were noted. Ranitidine is stable for seven days at room temperature and 30 days at 4 degrees C at all concentrations and in all vehicles studied. At the studied concentrations, the drug is stable in admixtures frozen for 60 days and stored for seven days at room temperature or 14 days refrigerated, except in DLR admixtures; these admixtures should not be stored frozen.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2220860

Source DB:  PubMed          Journal:  Am J Hosp Pharm        ISSN: 0002-9289


  1 in total

1.  Physical Compatibility and Chemical Stability of Injectable and Oral Ranitidine Solutions.

Authors:  Kelly Fleming; Ronald F Donnelly
Journal:  Hosp Pharm       Date:  2018-03-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.